NEW YORK — Quotient has signed an agreement to supply its SARS-CoV-2 antibody microarray test to Hvivo, a UK-based contract research organization specializing in viral challenge studies, the companies said on Monday.
Quotient's MosaiQ COVID-19 Antibody Microarray is designed to detect human immunoglobulin G and M antibodies against SARS-CoV-2 and runs on the company's Mosaiq automated testing system. Both the test and the system are CE marked.
Under the terms of the deal, Eysins, Switzerland-based Quotient will be Hvivo's exclusive supplier of SARS-CoV-2 antibody testing equipment, providing it with the microarray test and Mosaiq system. Additional terms were not disclosed.
Hvivo is a subsidiary of pharmaceutical services firm Open Orphan.